Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 942 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... December 17, 2020 EMA Recommends Extension of Indications for Tafasitamab December 4, 2025 Tumors With KRAS G12C Mutation Respond to Adagrasib and Using Toripalimab... April 19, 2023 Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor,... February 9, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Decitabine / Cedazuridine CAR22 Shows Durable Efficacy After a Single Infusion in Patients with... EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the... In the Name of Pinkness
